185 related articles for article (PubMed ID: 8308885)
1. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
2. Conformational properties of topoisomerase II inhibitors and sequence specificity of DNA cleavage.
Palumbo M; Mabilia M; Pozzan A; Capranico G; Tinelli S; Zunino F
J Mol Recognit; 1994 Sep; 7(3):227-31. PubMed ID: 7880548
[TBL] [Abstract][Full Text] [Related]
3. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
4. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety.
Capranico G; Butelli E; Zunino F
Cancer Res; 1995 Jan; 55(2):312-7. PubMed ID: 7812964
[TBL] [Abstract][Full Text] [Related]
5. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
[TBL] [Abstract][Full Text] [Related]
6. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
[TBL] [Abstract][Full Text] [Related]
7. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
8. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
9. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
10. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
[TBL] [Abstract][Full Text] [Related]
11. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
12. Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.
Capranico G; Guano F; Moro S; Zagotto G; Sissi C; Gatto B; Zunino F; Menta E; Palumbo M
J Biol Chem; 1998 May; 273(21):12732-9. PubMed ID: 9582297
[TBL] [Abstract][Full Text] [Related]
13. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
14. Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidin: sequence specificity and structural drug determinants.
Binaschi M; Zagotto G; Palumbo M; Zunino F; Farinosi R; Capranico G
Cancer Res; 1997 May; 57(9):1710-6. PubMed ID: 9135013
[TBL] [Abstract][Full Text] [Related]
15. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
16. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
17. Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin.
Henichart JP; Waring MJ; Riou JF; Denny WA; Bailly C
Mol Pharmacol; 1997 Mar; 51(3):448-61. PubMed ID: 9058600
[TBL] [Abstract][Full Text] [Related]
18. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.
Lown JW; Hanstock CC; Bradley RD; Scraba DG
Mol Pharmacol; 1984 Jan; 25(1):178-84. PubMed ID: 6708933
[TBL] [Abstract][Full Text] [Related]
20. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains.
Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M
Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
